Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines.

Division of Molecular Neurobiology, Brain Research Institute, Niigata University, 1-757 Asahimachi, Niigata, Japan.
Neuroscience Research (Impact Factor: 2.15). 10/2006; 56(1):2-13. DOI: 10.1016/j.neures.2006.06.002
Source: PubMed

ABSTRACT Epidemiologic studies demonstrate significant environmental impact of maternal viral infection and obstetric complications on the risk of schizophrenia and indicate their detrimental influences on brain development in this disorder. Based on these findings, animal models for schizophrenia have been established using double stranded RNA, bacterial lipopolysaccharides, hippocampal lesion, or prenatal/perinatal ischemia. Key molecules regulating such immune/inflammatory reactions are cytokines, which are also involved in brain development, regulating dopaminergic and GABAergic differentiation, and synaptic maturation. Specific members of the cytokine family, such as interleukin-1, epidermal growth factor, and neuregulin-1, are induced after infection and brain injury; therefore, certain cytokines are postulated to have a central role in the neurodevelopmental defects of schizophrenia. Recently, to test this hypothesis, a variety of cytokines were administered to rodent pups. Cytokines administered in the periphery penetrated the immature blood-brain barrier and perturbed phenotypic neural development. Among the many cytokines examined, epidermal growth factor (or potentially other ErbB1 ligands) and interleukin-1 specifically induced the most severe and persistent behavioral and cognitive abnormalities, most of which were ameliorated by antipsychotics. These animal experiments illustrate that, during early development, these cytokine activities in the periphery perturbs normal brain development and impairs later psychobehavioral and/or cognitive traits. The neurodevelopmental and behavioral consequences of prenatal/perinatal cytokine activity are compared with those of other schizophrenia models and cytokine interactions with genes are also discussed in this review.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Autism spectrum disorders (ASD) are neurodevelopmental disorders characterized by deficits in social interactions, communication, and increased stereotypical repetitive behaviors. The immune system plays an important role in neurodevelopment, regulating neuronal proliferation, synapse formation and plasticity, as well as removing apoptotic neurons. Immune dysfunction in ASD has been repeatedly described by many research groups across the globe. Symptoms of immune dysfunction in ASD include neuroinflammation, presence of autoantibodies, increased T cell responses, and enhanced innate NK cell and monocyte immune responses. Moreover these responses are frequently associated with more impairment in core ASD features including impaired social interactions, repetitive behaviors and communication. In mouse models replacing immune components in animals that exhibit autistic relevant features leads to improvement in behavior in these animals. Taken together this research suggests that the immune dysfunction often seen in ASD directly affects aspects of neurodevelopment and neurological processes leading to changes in behavior. Discussion of immune abnormalities in ASD will be the focus of this review. Copyright © 2014. Published by Elsevier B.V.
    Immunology Letters 11/2014; 163(1):49-55. · 2.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Alterations in immune function have been implicated in the aetiopathogenesis of schizophrenia. Specifically, the induction of inflammatory cytokines, which are important immunological factors in infection or inflammation, may be critical factors altering the normal course of brain development and increasing schizophrenia risk. Suppressor of cytokine signalling 2 (SOCS2) can negatively regulate the signalling of cytokines. The present study aimed to determine the behavioural phenotype of transgenic mice over-expressing SOCS2 (SOCS2 Tg) in paradigms of relevance to schizophrenia. Both male and female SOCS2 Tg mice displayed reduced locomotor hyperactivity after the administration of the dopamine releaser, amphetamine, compared to wildtype controls (WT). However, only male SOCS2 Tg mice showed enhanced prepulse inhibition compared to WT. Dopamine D2 receptors mRNA expression was reduced and dopamine transporter mRNA expression was increased in the nucleus accumbens of female, but not male, SOCS2 Tg mice, compared to WT. The role of hyperdopaminergia has long been implicated in the aetiology of schizophrenia. This study shows that over-expression of SOCS2 reduces the psychostimulant effects of amphetamine, enhances PPI, and alters mesolimbic dopaminergic activity. SOCS2 may provide a novel target in the development of treatments for schizophrenia.
    Progress in Neuro-Psychopharmacology and Biological Psychiatry 10/2014; · 4.03 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background There is a long standing interest in investigating the impact of early-life immune abnormalities on later onset of psychosis. The aim of this study was to assess inflammatory marker levels in neonatal dried blood spots and their association with later risk of schizophrenia. Method This nested case-control study included 995 cases and 980 controls. Cases were identified using the Danish Psychiatric Central Register. Controls of same age and sex were identified using the Danish Civil Registration System. Samples for the identified individuals were retrieved from the Danish Neonatal Screening Biobank. Concentrations of 17 inflammatory markers were measured in eluates from dried blood spots using a bead-based multiplex assay. Incidence rate ratios were calculated using conditional logistic regression. Principal component analysis was used to capture the overall variation in the inflammatory marker’s concentrations. Results No significant differences were found for any of the analyzed interleukins. We did not find any association with schizophrenia for any of the other examined inflammatory markers. Conclusion Our results suggest that persons who develop schizophrenia do not have higher or lower levels of the examined inflammatory markers at the time of birth. Our findings differ from the studies of maternal inflammatory changes during the antenatal period for which associations with schizophrenia have previously been demonstrated.
    Biological Psychiatry 07/2014; · 9.47 Impact Factor